Paper Details

  1. Home
  2. Paper Details

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.

Author: KadhiravanTamilarasu, SharmaAnju, SharmaSurendra K, TharyanPrathap

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Preventing active tuberculosis (TB) in people with latent TB infection (LTBI) is crucial for global TB control. While isoniazid (INH) is effective (60-90% protection), it has a long treatment period, can cause liver problems, and is only taken by about half of people outside of studies. Shorter treatments with rifampicin or rifamycin combinations may improve completion rates.
Paper Details　
Original Abstract of the Article :
Preventing active tuberculosis (TB) from developing in people with latent tuberculosis infection (LTBI) is important for global TB control. Isoniazid (INH) for six to nine months has 60% to 90% protective efficacy, but the treatment period is long, liver toxicity is a problem, and completion rates o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532682/

データ提供：米国国立医学図書館（NLM）

Preventing Tuberculosis: Rifamycins vs. Isoniazid

This research focuses on the [prevention of active tuberculosis (TB)] in [individuals with latent tuberculosis infection (LTBI)]. The researchers [compare the efficacy of rifamycins (rifampicin, rifabutin, and rifapentine) to isoniazid (INH)], [two common medications] used for preventing TB. The study aimed to [evaluate the effectiveness and feasibility] of these treatment options.

Rifamycins: A Promising Alternative for TB Prevention

The study [highlights the potential of rifamycins] as [a shorter and potentially more effective] treatment option for [preventing TB] compared to INH. The researchers [emphasize the need for further research] to [confirm the superiority of rifamycins] and [explore the optimal duration and regimens] for this treatment approach. This research is like a [desert trail], [leading us towards] [more efficient and effective] strategies for preventing TB.

Optimizing TB Prevention Strategies

This research [underscores the importance of developing] [effective and well-tolerated treatment options] for [preventing TB] in individuals with [LTBI]. The findings [emphasize the need for ongoing research] to [optimize TB prevention strategies] and [reduce the global burden of TB]. This research is like a [desert expedition], [seeking new solutions] to [address this ongoing public health challenge].

Dr.Camel's Conclusion

This research [explores the potential of rifamycins] as [a promising alternative] to INH for [preventing TB] in individuals with [LTBI]. The findings [highlight the need for further research] to [optimize the use of rifamycins] and [improve global TB control]. This research is like a [desert oasis], [offering hope] for [better TB prevention strategies].

Date :
  1. Date Completed 2013-12-20
  2. Date Revised 2023-11-04
Further Info :

Pubmed ID

23828580

DOI: Digital Object Identifier

PMC6532682

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.